HMN 2025: How Empagliflozin has kidney protecting results in acute myocardial infarction

Empagliflozin has kidney protecting results and reduces coronary heart failure outcomes throughout baseline kidney perform amongst sufferers with acute myocardial infarction (MI), based on a review published on-line June 13 in Nature Cardiovascular Research.

Rahul Aggarwal, M.D., from Harvard Medical School in Boston, and colleagues examined the cardiovascular-kidney results and security of empagliflozin in a secondary evaluation of a multicenter, medical trial involving 6,522 sufferers with acute MI and danger for coronary heart failure who had been randomly allotted to obtain empagliflozin or placebo.

The researchers discovered that the imply estimated glomerular filtration fee at baseline was 76.1 mL/min/1.73 m²; longitudinal kidney perform knowledge had been obtainable for 1,152 handled sufferers from choose nations. Compared with baseline, by 24 months, the estimated glomerular filtration fee was related within the empagliflozin group, however decreased within the placebo group.

Irrespective of kidney perform, the full antagonistic occasions of coronary heart failure or all-cause mortality had been diminished with empagliflozin. Similar 30-day antagonistic occasion charges had been seen by therapy group, which had been constant throughout baseline kidney perform.

“Empagliflozin demonstrated helpful kidney-protective results, diminished coronary heart failure outcomes and was secure to provoke quickly after acute MI,” the authors write. “The cardiovascular-kidney advantages and security of empagliflozin had been constant no matter baseline kidney perform.”

Several authors disclosed ties to biopharmaceutical corporations; the review was funded by the Boehringer Ingelheim and Eli Lilly and Company Alliance.

© 2025 .